Literature DB >> 21848129

Conditional survival analyses across cancer sites.

Larry F Ellison1, Heather Bryant, Gina Lockwood, Lorraine Shack.   

Abstract

Survival estimates measured from the time cancer diagnosis become less informative after one or two years' survival. Using records from the Canadian Cancer Registry linked to the Canadian Vital Statistics Death Database, five-year conditional relative survival ratio (RSR) estimates were derived for a large number of cancers. For each cancer with an initial five-year RSR of at least 80% (except breast cancer), a conditional five-year RSR of 95% or more was achieved after five years' survival. Among cancers with initial five-year RSRs of 50% to 79%, a five-year conditional RSR of 95% or more was observed for cancers of the cervix uteri and colon after five years. There was no apparent improvement in survival prospects during the first five years after diagnosis for chronic lymphocytic leukemia (CLL). Despite initial prognoses of less than 50%, a conditional five-year RSR of at least 90% five years after diagnosis was achieved for stomach cancer and leukemia (excluding CLL).

Entities:  

Mesh:

Year:  2011        PMID: 21848129

Source DB:  PubMed          Journal:  Health Rep        ISSN: 0840-6529            Impact factor:   4.796


  22 in total

1.  Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length.

Authors:  Eric M Ammann; Tait D Shanafelt; Kara B Wright; Bradley D McDowell; Brian K Link; Elizabeth A Chrischilles
Journal:  Leuk Lymphoma       Date:  2017-07-18

2.  Bladder cancer: Conditional survival after radical cystectomy.

Authors:  Giorgio Gandaglia; Maxine Sun
Journal:  Nat Rev Urol       Date:  2013-12-17       Impact factor: 14.432

3.  Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands.

Authors:  Saskia A M van de Schans; Liza N van Steenbergen; Jan Willem W Coebergh; Maryska L G Janssen-Heijnen; Dick Johan van Spronsen
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

4.  Provincial rates and time trends in pancreatic cancer outcomes.

Authors:  S Fung; T Forte; R Rahal; J Niu; H Bryant
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

5.  Rectal cancer resection and circumferential margin rates in Canada: a population-based study.

Authors:  K DeCaria; R Rahal; J Niu; G Lockwood; H Bryant
Journal:  Curr Oncol       Date:  2015-02       Impact factor: 3.677

6.  Conditional survival in Canada: adjusting patient prognosis over time.

Authors:  H Bryant; G Lockwood; R Rahal; L Ellison
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

7.  Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy.

Authors:  Alfonso Quintás-Cardama; Sangbum Choi; Hagop Kantarjian; Elias Jabbour; Xuelin Huang; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-01-15

8.  Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis.

Authors:  Marcus C B Tan; Jean M Butte; Mithat Gonen; Nancy Kemeny; Yuman Fong; Peter J Allen; T Peter Kingham; Ronald P Dematteo; William R Jarnagin; Michael I D'Angelica
Journal:  HPB (Oxford)       Date:  2013-06-19       Impact factor: 3.647

9.  Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data.

Authors:  Yuri Ito; Isao Miyashiro; Hidemi Ito; Satoyo Hosono; Dai Chihara; Kayo Nakata-Yamada; Masashi Nakayama; Masashi Matsuzaka; Masakazu Hattori; Hiromi Sugiyama; Isao Oze; Rina Tanaka; Etsuko Nomura; Yoshikazu Nishino; Tomohiro Matsuda; Akiko Ioka; Hideaki Tsukuma; Tomio Nakayama
Journal:  Cancer Sci       Date:  2014-10-18       Impact factor: 6.716

10.  Conditional survival of cancer patients: an Australian perspective.

Authors:  Xue Qin Yu; Peter D Baade; Dianne L O'Connell
Journal:  BMC Cancer       Date:  2012-10-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.